Literature DB >> 11134127

Alterations in plasma transforming growth factor beta in normoalbuminuric type 1 and type 2 diabetic patients.

S T Azar1, I Salti, M S Zantout, S Major.   

Abstract

Transforming growth factor ss (TGF-ss) is an immunosuppressor. It plays a role in regulating cell proliferation, and deletion of its gene in transgenic mice leads to an autoimmune-like disorder. A role of this cytokine has been proposed in the pathogenesis of type 1 diabetes and probably type 2 diabetes. Previous studies had shown an elevated serum level in type 2 diabetes and a reduced serum level in type 1 diabetes; however, these studies did not address the onset of the alterations of TGF-ss with regard to the duration of diabetes. In this study, we compared the levels of TGF-ss in the serum of groups of patients with type 1 and type 2 diabetes mellitus divided according to the duration of their disease. Twenty-six normoalbuminuric patients with type 1 diabetes and 25 normoalbuminuric patients with type 2 diabetes were divided into three groups according to the onset of their diabetes and were compared with 27 and 15 age-matched normal subjects, respectively. We conclude that in normoalbuminuric patients serum TGF-ss levels increased at the onset of type 2 diabetes and remained elevated throughout the disease; they did not change at the onset of type1 diabetes, however, they started to decrease around 2 yr after the onset of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11134127     DOI: 10.1210/jcem.85.12.7073

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus.

Authors:  D Westermann; S Rutschow; S Van Linthout; A Linderer; C Bücker-Gärtner; M Sobirey; A Riad; M Pauschinger; H-P Schultheiss; C Tschöpe
Journal:  Diabetologia       Date:  2006-08-26       Impact factor: 10.122

Review 2.  Targeting regulatory T cells in the treatment of type 1 diabetes mellitus.

Authors:  S M Cabrera; M R Rigby; R G Mirmira
Journal:  Curr Mol Med       Date:  2012-12       Impact factor: 2.222

3.  Antipsychotics activate the TGFβ pathway effector SMAD3.

Authors:  T Cohen; S Sundaresh; F Levine
Journal:  Mol Psychiatry       Date:  2012-01-31       Impact factor: 15.992

4.  Overproduction of phosphoprotein enriched in diabetes (PED) induces mesangial expansion and upregulates protein kinase C-beta activity and TGF-beta1 expression.

Authors:  F Oriente; S Iovino; A Cassese; C Romano; C Miele; G Troncone; M Balletta; A Perfetti; G Santulli; G Iaccarino; R Valentino; F Beguinot; P Formisano
Journal:  Diabetologia       Date:  2009-09-30       Impact factor: 10.122

5.  Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy.

Authors:  L Adhikary; F Chow; D J Nikolic-Paterson; C Stambe; J Dowling; R C Atkins; G H Tesch
Journal:  Diabetologia       Date:  2004-07-01       Impact factor: 10.122

Review 6.  Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:  Yong-Chao Qiao; Jian Shen; Lan He; Xue-Zhi Hong; Fang Tian; Yan-Hong Pan; Ling Liang; Xiao-Xi Zhang; Hai-Lu Zhao
Journal:  J Diabetes Res       Date:  2016-09-29       Impact factor: 4.011

7.  Circulating TGF-β1, glycation, and oxidation in children with diabetes mellitus type 1.

Authors:  Vladimír Jakuš; Michal Sapák; Jana Kostolanská
Journal:  Exp Diabetes Res       Date:  2012-09-26

Review 8.  Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers.

Authors:  Camelia R Ban; Stephen M Twigg
Journal:  Vasc Health Risk Manag       Date:  2008

9.  Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype.

Authors:  Irene Vinagre; José Luis Sánchez-Quesada; Juan Sánchez-Hernández; David Santos; Jordi Ordoñez-Llanos; Alberto De Leiva; Antonio Pérez
Journal:  Cardiovasc Diabetol       Date:  2014-02-04       Impact factor: 9.951

10.  Serum IL-17, IL-23, and TGF-β levels in type 1 and type 2 diabetic patients and age-matched healthy controls.

Authors:  Azam Roohi; Mina Tabrizi; Farzaneh Abbasi; Asal Ataie-Jafari; Behrouz Nikbin; Bagher Larijani; Mostafa Qorbani; Alipasha Meysamie; Hossein Asgarian-Omran; Bahram Nikmanesh; Arezou Bajouri; Novin Shafiey; Akram Maleki
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.